Nature provides us with countless chemicals that can improve our lives. Trees and plants often supply them, but in such small amounts that they’re hard to extract, leading to waste and environmental degradation. To harness natural chemicals more effectively, synthetic biology first attempted to rewire living cells to make them easier to extract. But cells are complicated and not easily rewired.
Invizyne’s new approach, SimplePath streamlines synthetic biology by removing cells altogether, along with their complexities. Using our proprietary, sustainable enzyme systems we can build simple, efficient reactors for chemical production.
Company Details
- Employees
- 38
- Founded
- -
- Address
- Monrovia, California, Us
- Industry
- Biotechnology
- Website
- https://www.invizyne.com/
- Keywords
- synthetic biology, SynBio, cell free, biotechnology, biomanufacturing, natural chemicals, enzymatic pathways, chemicals, pharmaceuticals, cannabinoids.
- HQ
- Monrovia, California
Exozymes (Nasdaq: Exoz) Questions
Exozymes (Nasdaq: Exoz)'s website is https://www.invizyne.com/
Exozymes (Nasdaq: Exoz)'s LinkedIn profile is https://www.linkedin.com/company/exozymes
Exozymes (Nasdaq: Exoz) has
38 employees.
View email and phone details for 38
employees at Exozymes (Nasdaq: Exoz).
Exozymes (Nasdaq: Exoz)'s industry is
Biotechnology
Exozymes (Nasdaq: Exoz)'s top competitors are
Codexis, Inc.,
Ginkgo Bioworks, Inc.,
Bota Biosciences,
Biomade,
Cascade Bio,
Aminoverse,
Enginzyme,
Mdb Capital,
Tierra Biosciences,
Caravel Bio.
Exozymes (Nasdaq: Exoz)'s categories are Biotechnology
Exozymes (Nasdaq: Exoz)'s founding year is 2014
